Erytech Pharma Inc.
One Main Street
Suite 300
Cambridge
MA
02142
United States
Tel: +1-857-706-1585
Website: http://www.erytech.com/
Email: contact-usa@erytech.com
205 articles about Erytech Pharma Inc.
-
ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019
11/5/2019
ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells
-
ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
11/4/2019
ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced two important milestones for the TRYbeCA1 Phase 3 clinical trial of eryaspase in second line metastatic pancreatic cancer.
-
ERYTECH Expands Use of Medidata Cloud to Centrally Manage All Data for Oncology Trials
11/7/2018
French biopharmaceutical company aims to improve data access, quality, and workflow efficiencies
-
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
6/15/2018
ERYTECH Pharma announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) at the European Hematology Association (EHA) Congress
-
LYONBIOPOLE Will Unite Leading French Biotech Actors at the 2018 BIO International Convention
5/31/2018
Lyonbiopole the French "bio-cluster" based in the Auvergne-Rhône-Alpes region, will unite 35 innovative organizations at the 2018 edition of the BIO International Convention.
-
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
2/13/2018
Following these very encouraging results, ERYTECH conducted a comprehensive evaluation to determine other potential solid-tumor indications for developing eryaspase.
-
The study enrolled a total of 123 patients at 30 European sites.
-
French Biotech ERYTECH Enters the Nasdaq and Raises $144M
11/15/2017
Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017.
-
ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017
11/13/2017
ERYTECH announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.
-
ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update
11/7/2017
Net loss for the nine-month period ended September 30, 2017 was €20.8 million, compared to €16.1 million for the same period in the prior year.
-
ERYtech Pharma Announces Resubmission Of European Marketing Authorization Application For GRASPA In Acute Lymphoblastic Leukemia
10/10/2017
-
France-Based ERYtech Pharma Files for $100 Million IPO
10/9/2017
-
ERYtech Pharma Reports Determination Of The Recommended Pivotal Phase 3 Dose Of Eryaspase In Its U.S. Phase 1 Study In First Line Adult ALL
9/28/2017
-
ERYtech Pharma Reports First Half 2017 Financial Results And Provides Business Update
9/11/2017
-
ERYtech Pharma Announces Positive Full Results From Phase IIb Study Of Eryaspase In Combination With Chemotherapy For Treatment Of Metastatic Pancreatic Cancer In Second-Line
9/8/2017
-
ERYtech PharmaTo Host Second Quarter 2017 Conference Call And Business Update
9/6/2017
-
ERYtech Pharma To Present Pre-Clinical Data At The 13th International Congress Of Inborn Errors Of Metabolism
9/1/2017
-
ERYtech Pharma To Present Full Results For Phase IIb Trial Of Eryaspase In Pancreatic Cancer At ESMO 2017
8/31/2017
-
ERYtech Pharma Announces Collaboration With Queen’s University To Advance Its Product Candidate For Rare Metabolic Disorders
7/12/2017
-
ERYtech Pharma Provides Business Update And Financial Highlights For Q1 2017
5/19/2017